You just read:

Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs

News provided by

Kindred Biosciences, Inc.

Mar 24, 2020, 08:31 ET